In a large, NIDDK-funded clinical trial comparing commonly used type 2 diabetes medications, researchers found that insulin glargine and liraglutide performed the best of four medications FDA-approved to maintain blood glucose levels in the recommended range.

A new NIH study has found that a medication for heart problems and high blood pressure may also be effective for treating alcohol use disorder (AUD).

Steroid treatment before birth appears to improve survival and reduce complications among extremely preterm infants, according to a recent NIH study funded by NICHD and NCATS.

NEI intramural researchers have shown for the first time how cells across different tissue layers in the eye are affected in people with choroideremia, a rare genetic disorder that leads to blindness.

A noninvasive stimulation technique targeting specific brain regions resulted in month-long memory improvements in seniors who participated in a recent study.

NIH researchers have found that dual bronchodilators—long-lasting inhalers that relax the airways and make it easier to breathe—do little to help people who have respiratory symptoms related to smoking but who do not have chronic obstructive pulmonary disease (COPD).

NIH researchers have found that a novel blood test can easily evaluate disease severity in patients with pulmonary arterial hypertension (PAH) and predict survivability. PAH is a rare, life-threatening condition that causes unexplained high blood pressure in the lungs.

A prospective study of a half-million tea drinkers in the United Kingdom has shown that higher tea intake was associated with a modestly lowered risk of death.

In a new study, NIAID researchers analyzed levels of SARS-CoV-2 antigen in blood samples taken from study participants and assessed the association of those levels with disease progression.

ne injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a NIAID phase 1 clinical trial.